Ontology type: schema:ScholarlyArticle
2014-05-08
AUTHORSPierre-Yves Salaun, Loïc Campion, Catherine Ansquer, Eric Frampas, Cédric Mathieu, Philippe Robin, Claire Bournaud, Jean-Philippe Vuillez, David Taieb, Caroline Rousseau, Delphine Drui, Eric Mirallié, Françoise Borson-Chazot, David M. Goldenberg, Jean-François Chatal, Jacques Barbet, Françoise Kraeber-Bodéré
ABSTRACTPurposePET is a powerful tool for assessing targeted therapy. Since 18F-FDG shows a potential prognostic value in medullary thyroid carcinoma (MTC), this study evaluated 18F-FDG PET alone and combined with morphological and biomarker evaluations as a surrogate marker of overall survival (OS) in patients with progressive metastatic MTC treated with pretargeted anti-CEA radioimmunotherapy (pRAIT) in a phase II clinical trial.MethodsPatients underwent PET associated with morphological imaging (CT and MRI) and biomarker evaluations, before and 3 and 6 months, and then every 6 months, after pRAIT for 36 months. A combined evaluation was performed using anatomic, metabolic and biomarker methods. The prognostic value of the PET response was compared with demographic parameters at inclusion including age, sex, RET mutation, time from initial diagnosis, calcitonin and CEA concentrations and doubling times (DT), SUVmax, location of disease and bone marrow involvement, and with response using RECIST, biomarker concentration variation, impact on DT, and combined methods.ResultsEnrolled in the study were 25 men and 17 women with disease progression. The median OS from pRAIT was 3.7 years (0.2 to 6.5 years) and from MTC diagnosis 10.9 years (1.7 to 31.5 years). After pRAIT, PET/CT showed 1 patient with a complete response, 4 with a partial response and 24 with disease stabilization. The combined evaluation showed 20 responses. For OS from pRAIT, univariate analysis showed the prognostic value of biomarker DT (P = 0.011) and SUVmax (P = 0.038) calculated before pRAIT and impact on DT (P = 0.034), RECIST (P = 0.009), PET (P = 0.009), and combined response (P = 0.004) measured after pRAIT. PET had the highest predictive value with the lowest Akaike information criterion (AIC 74.26) as compared to RECIST (AIC 78.06), biomarker variation (AIC 81.94) and impact on DT (AIC 79.22). No benefit was obtained by combining the methods (AIC 78.75). This result was confirmed by the analysis of OS from MTC diagnosis.Conclusion18F-FDG PET appeared as the most potent and simplest prognostic method to predict survival in patients with progressive MTC treated with pRAIT. Biomarker DT before pRAIT also appeared as an independent prognostic factor, but no benefit was found by adding morphological and biomarker evaluation to PET assessment. More... »
PAGES1501-1510
http://scigraph.springernature.com/pub.10.1007/s00259-014-2772-0
DOIhttp://dx.doi.org/10.1007/s00259-014-2772-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1031925914
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/24806110
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged, 80 and over",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Carcinoma, Medullary",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Carcinoma, Neuroendocrine",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Fluorodeoxyglucose F18",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multimodal Imaging",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Positron-Emission Tomography",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Predictive Value of Tests",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Radioimmunotherapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Radiopharmaceuticals",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Thyroid Neoplasms",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Tomography, X-Ray Computed",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Brest, France",
"id": "http://www.grid.ac/institutes/grid.411766.3",
"name": [
"Nuclear Medicine Department, University Hospital, Brest, France"
],
"type": "Organization"
},
"familyName": "Salaun",
"givenName": "Pierre-Yves",
"id": "sg:person.01021766527.49",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021766527.49"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Statistical Department, ICO-Gauducheau Cancer Institute, Nantes, France",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Statistical Department, ICO-Gauducheau Cancer Institute, Nantes, France"
],
"type": "Organization"
},
"familyName": "Campion",
"givenName": "Lo\u00efc",
"id": "sg:person.01100327307.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100327307.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Nantes, France",
"id": "http://www.grid.ac/institutes/grid.277151.7",
"name": [
"Nuclear Medicine Department, University Hospital, Nantes, France"
],
"type": "Organization"
},
"familyName": "Ansquer",
"givenName": "Catherine",
"id": "sg:person.01050273323.41",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050273323.41"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nantes-Angers Cancer Research Center, Inserm, U 892, CNRS, UMR 6299, Universit\u00e9 de Nantes, Nantes, France",
"id": "http://www.grid.ac/institutes/grid.4817.a",
"name": [
"Radiology Department, University Hospital, Nantes, France",
"Nantes-Angers Cancer Research Center, Inserm, U 892, CNRS, UMR 6299, Universit\u00e9 de Nantes, Nantes, France"
],
"type": "Organization"
},
"familyName": "Frampas",
"givenName": "Eric",
"id": "sg:person.0720415666.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0720415666.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Nantes, France",
"id": "http://www.grid.ac/institutes/grid.277151.7",
"name": [
"Nuclear Medicine Department, University Hospital, Nantes, France"
],
"type": "Organization"
},
"familyName": "Mathieu",
"givenName": "C\u00e9dric",
"id": "sg:person.01300720363.95",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300720363.95"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Brest, France",
"id": "http://www.grid.ac/institutes/grid.411766.3",
"name": [
"Nuclear Medicine Department, University Hospital, Brest, France"
],
"type": "Organization"
},
"familyName": "Robin",
"givenName": "Philippe",
"id": "sg:person.01307140060.86",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307140060.86"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Lyon, France",
"id": "http://www.grid.ac/institutes/grid.413852.9",
"name": [
"Nuclear Medicine Department, University Hospital, Lyon, France"
],
"type": "Organization"
},
"familyName": "Bournaud",
"givenName": "Claire",
"id": "sg:person.01060766754.34",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060766754.34"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Grenoble, France",
"id": "http://www.grid.ac/institutes/grid.410529.b",
"name": [
"Nuclear Medicine Department, University Hospital, Grenoble, France"
],
"type": "Organization"
},
"familyName": "Vuillez",
"givenName": "Jean-Philippe",
"id": "sg:person.01171243155.07",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01171243155.07"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, University Hospital, Marseille, France",
"id": "http://www.grid.ac/institutes/grid.414336.7",
"name": [
"Nuclear Medicine Department, University Hospital, Marseille, France"
],
"type": "Organization"
},
"familyName": "Taieb",
"givenName": "David",
"id": "sg:person.0712575061.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0712575061.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, ICO-Ren\u00e9 Gauducheau, Nantes, France",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Nantes-Angers Cancer Research Center, Inserm, U 892, CNRS, UMR 6299, Universit\u00e9 de Nantes, Nantes, France",
"Nuclear Medicine Department, ICO-Ren\u00e9 Gauducheau, Nantes, France"
],
"type": "Organization"
},
"familyName": "Rousseau",
"givenName": "Caroline",
"id": "sg:person.01240530667.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01240530667.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Endocrinology Department, University Hospital, Nantes, France",
"id": "http://www.grid.ac/institutes/grid.277151.7",
"name": [
"Endocrinology Department, University Hospital, Nantes, France"
],
"type": "Organization"
},
"familyName": "Drui",
"givenName": "Delphine",
"id": "sg:person.01116406523.45",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01116406523.45"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Surgery Department, University Hospital, Nantes, France",
"id": "http://www.grid.ac/institutes/grid.277151.7",
"name": [
"Surgery Department, University Hospital, Nantes, France"
],
"type": "Organization"
},
"familyName": "Miralli\u00e9",
"givenName": "Eric",
"id": "sg:person.01123460061.71",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01123460061.71"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Endocrinology Department, University Hospital, Lyon, France",
"id": "http://www.grid.ac/institutes/grid.413852.9",
"name": [
"Endocrinology Department, University Hospital, Lyon, France"
],
"type": "Organization"
},
"familyName": "Borson-Chazot",
"givenName": "Fran\u00e7oise",
"id": "sg:person.01016420620.30",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016420620.30"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA",
"id": "http://www.grid.ac/institutes/grid.280985.e",
"name": [
"IBC Pharmaceuticals, Inc., and Immunomedics, Inc., Morris Plains, NJ, USA",
"Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA"
],
"type": "Organization"
},
"familyName": "Goldenberg",
"givenName": "David M.",
"id": "sg:person.0744776153.57",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0744776153.57"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "GIP ARRONAX, Saint-Herblain, France",
"id": "http://www.grid.ac/institutes/None",
"name": [
"GIP ARRONAX, Saint-Herblain, France"
],
"type": "Organization"
},
"familyName": "Chatal",
"givenName": "Jean-Fran\u00e7ois",
"id": "sg:person.0623457423.87",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623457423.87"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "GIP ARRONAX, Saint-Herblain, France",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Nantes-Angers Cancer Research Center, Inserm, U 892, CNRS, UMR 6299, Universit\u00e9 de Nantes, Nantes, France",
"GIP ARRONAX, Saint-Herblain, France"
],
"type": "Organization"
},
"familyName": "Barbet",
"givenName": "Jacques",
"id": "sg:person.01001654663.28",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001654663.28"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Nuclear Medicine Department, H\u00f4tel Dieu University Hospital, 1 place Ricordeau, 44093, Nantes, France",
"id": "http://www.grid.ac/institutes/None",
"name": [
"Nuclear Medicine Department, University Hospital, Nantes, France",
"Nantes-Angers Cancer Research Center, Inserm, U 892, CNRS, UMR 6299, Universit\u00e9 de Nantes, Nantes, France",
"Nuclear Medicine Department, ICO-Ren\u00e9 Gauducheau, Nantes, France",
"Nuclear Medicine Department, H\u00f4tel Dieu University Hospital, 1 place Ricordeau, 44093, Nantes, France"
],
"type": "Organization"
},
"familyName": "Kraeber-Bod\u00e9r\u00e9",
"givenName": "Fran\u00e7oise",
"id": "sg:person.0653324404.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653324404.03"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/sj.bjc.6601453",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1025587905",
"https://doi.org/10.1038/sj.bjc.6601453"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/nrclinonc.2011.160",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015794593",
"https://doi.org/10.1038/nrclinonc.2011.160"
],
"type": "CreativeWork"
}
],
"datePublished": "2014-05-08",
"datePublishedReg": "2014-05-08",
"description": "PurposePET is a powerful tool for assessing targeted therapy. Since 18F-FDG shows a potential prognostic value in medullary thyroid carcinoma (MTC), this study evaluated 18F-FDG PET alone and combined with morphological and biomarker evaluations as a surrogate marker of overall survival (OS) in patients with progressive metastatic MTC treated with pretargeted anti-CEA radioimmunotherapy (pRAIT) in a phase II clinical trial.MethodsPatients underwent PET associated with morphological imaging (CT and MRI) and biomarker evaluations, before and 3 and 6\u00a0months, and then every 6\u00a0months, after pRAIT for 36\u00a0months. A combined evaluation was performed using anatomic, metabolic and biomarker methods. The prognostic value of the PET response was compared with demographic parameters at inclusion including age, sex, RET mutation, time from initial diagnosis, calcitonin and CEA concentrations and doubling times (DT), SUVmax, location of disease and bone marrow involvement, and with response using RECIST, biomarker concentration variation, impact on DT, and combined methods.ResultsEnrolled in the study were 25 men and 17 women with disease progression. The median OS from pRAIT was 3.7\u00a0years (0.2 to 6.5\u00a0years) and from MTC diagnosis 10.9\u00a0years (1.7 to 31.5\u00a0years). After pRAIT, PET/CT showed 1 patient with a complete response, 4 with a partial response and 24 with disease stabilization. The combined evaluation showed 20 responses. For OS from pRAIT, univariate analysis showed the prognostic value of biomarker DT (P\u2009=\u20090.011) and SUVmax (P\u2009=\u20090.038) calculated before pRAIT and impact on DT (P\u2009=\u20090.034), RECIST (P\u2009=\u20090.009), PET (P\u2009=\u20090.009), and combined response (P\u2009=\u20090.004) measured after pRAIT. PET had the highest predictive value with the lowest Akaike information criterion (AIC 74.26) as compared to RECIST (AIC 78.06), biomarker variation (AIC 81.94) and impact on DT (AIC 79.22). No benefit was obtained by combining the methods (AIC 78.75). This result was confirmed by the analysis of OS from MTC diagnosis.Conclusion18F-FDG PET appeared as the most potent and simplest prognostic method to predict survival in patients with progressive MTC treated with pRAIT. Biomarker DT before pRAIT also appeared as an independent prognostic factor, but no benefit was found by adding morphological and biomarker evaluation to PET assessment.",
"genre": "article",
"id": "sg:pub.10.1007/s00259-014-2772-0",
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1297401",
"issn": [
"1619-7070",
"1619-7089"
],
"name": "European Journal of Nuclear Medicine and Molecular Imaging",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "8",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "41"
}
],
"keywords": [
"medullary thyroid carcinoma",
"progressive metastatic medullary thyroid carcinoma",
"metastatic medullary thyroid carcinoma",
"overall survival",
"prognostic value",
"biomarker evaluation",
"thyroid carcinoma",
"analysis of OS",
"progressive medullary thyroid carcinoma",
"phase II clinical trial",
"Conclusion18F-FDG PET",
"median overall survival",
"bone marrow involvement",
"independent prognostic factor",
"potential prognostic value",
"location of disease",
"PET/CT",
"high predictive value",
"combined evaluation",
"disease stabilization",
"marrow involvement",
"partial response",
"complete response",
"prognostic factors",
"initial diagnosis",
"PET response",
"PET assessment",
"surrogate marker",
"univariate analysis",
"clinical trials",
"disease progression",
"RET mutations",
"pretargeted radioimmunotherapy",
"MTC diagnosis",
"predictive value",
"patients",
"RECIST",
"morphological imaging",
"months",
"SUVmax",
"carcinoma",
"survival",
"radioimmunotherapy",
"CEA concentration",
"diagnosis",
"biomarker variation",
"PET",
"biomarker methods",
"response",
"combined response",
"MethodsPatients",
"therapy",
"evaluation",
"calcitonin",
"years",
"disease",
"trials",
"progression",
"CT",
"women",
"age",
"PurposePET",
"sex",
"dt",
"men",
"demographic parameters",
"markers",
"study",
"involvement",
"benefits",
"imaging",
"mutations",
"assessment",
"impact",
"factors",
"criteria",
"time",
"prognostic method",
"analysis",
"values",
"concentration",
"method",
"inclusion",
"information criterion",
"results",
"powerful tool",
"stabilization",
"tool",
"location",
"variation",
"parameters",
"concentration variations"
],
"name": "18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma",
"pagination": "1501-1510",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1031925914"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s00259-014-2772-0"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"24806110"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s00259-014-2772-0",
"https://app.dimensions.ai/details/publication/pub.1031925914"
],
"sdDataset": "articles",
"sdDatePublished": "2022-08-04T17:02",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_644.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1007/s00259-014-2772-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2772-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2772-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2772-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-014-2772-0'
This table displays all metadata directly associated to this object as RDF triples.
382 TRIPLES
21 PREDICATES
137 URIs
127 LITERALS
25 BLANK NODES